Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
By Thomas Duhen, Rebekka Duhen, R. Montler, Jake Moses, T. Moudgil, N. D. de Miranda, C. Goodall, T. Blair, B. Fox, J. Mcdermott and 5 more. Nature Communications, 2018
784 citations recorded by the source corpus.
Identifying tumor antigen-specific T cells from cancer patients has important implications for immunotherapy diagnostics and therapeutics. Here, we show that CD103+CD39+ tumor-infiltrating CD8 T cells (CD8 TIL) are enriched for tumor-reactive cells both in primary and metastatic tumors. This CD8 TIL subset is found across six different malignancies and displays an exhausted tissue-resident memory phenotype. CD103+CD39+ CD8 TILs have a distinct T-cell receptor (TCR) repertoire, with T-cell clones expanded in the tumor but present at low frequencies in the periphery. CD103+CD39+ CD8 TILs also efficiently kill autologous tumor cells in a MHC-class I-dependent manner. Finally, higher frequencies of CD103+CD39+ CD8 TILs in patients with head and neck cancer are associated with better overall survival. Our data thus describe an approach for detecting tumor-reactive CD8 TILs that will help define mechanisms of existing immunotherapy treatments, and may lead to future adoptive T-cell cancer therapies. Identifying and enumerating tumor-specific CD8 T cells are important for assessing cancer prognosis and therapy efficacy. Here the authors show that CD39 and CD103 mark a subset of tumor-infiltrating CD8 T cells that are tumor-reactive and exhibit characteristics of exhausted or tissue-resident memory T cells.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/6ef850a94cc9de6931a8a014bd6b31b5aa68fc04
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- N-N Xie
- G. Shen
- Wei Gao
- Zhao Huang
- Canhua Huang
- Li Fu
- H. Nijman
- S. Paijens
Citations in the corpus
- Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “, these DP CTLs exhibited more cytotoxic potential than DN CTLs, as more cells were granzyme-B positive, although this was not reflected in the production of IFNγ and TNFα.(28) CD4 TRM cells are also characterized by high expression of CD103, CD69, and CD49a and inhibitory molecules such as PD1, CTL”
- Neoantigens: promising targets for cancer therapy (2023, background): “Persistent exposure to TSAs promotes the exhaustion of CD8+ T cells, which characteristically expressed high levels of PD-1 and CD39.”